New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Item
http://www.wikidata.org/entity/Q34224278
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitorPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Mendelian disorders of the epigenetic machinery: tipping the balance of chromatin statesModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesRejuvenating sirtuins: the rise of a new family of cancer drug targetsNovel approaches to treatment of double-refractory multiple myeloma.Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilizationDesign, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold.Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.
P2860

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Item
http://www.wikidata.org/entity/Q34224278
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@ast
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@en
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@nl
type
label
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@ast
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@en
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@nl
prefLabel
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@ast
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@en
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
@en
P2093
P2860
P304
P31
P356
10.2174/138161213804581945
P433
P478
P50
P577
P698
P932